"The big boys are putting their clients in XOMA on the current pullback.""They know it's undervalued.""I expect the second week of January will be when they start initiating coverage "buy" and "strong buy" ratings and $15.00 price targets."Name one other bio-tech that has a drug with orphan drug status, $40,000,000 in cash on hand, no debt, and a market cap of just over $100 million dollars."
smittyWhy must you lie?They have lots of debt, jerkoff, and a negative cash and levered cash flow.
You're 100% correct.You won't here a word about XOMA's potential until they've put their major clients in the stock.The less "buzz" the cheaper they can buy shares.